Michael Miller, DO
Surgery · Indianapolis, INNPI 1730122268
Payments from drug & device makers
Across 1,018 payments — averaging $52.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- USWM, LLC$32K
- MDD US Operations, LLC$3K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Vanda Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $10K from 54 others
What the payments were for
- Consulting fees$1,2402%
- Speaking & faculty fees$24,05545%
- Travel & lodging$7,06513%
- Food & beverage$19,56337%
- Education$2500%
- Gifts$1,0202%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUCEMYRA$29,186
- SYMJEPI$3,681
- Lucemyra/Lofexidine$2,125
- CAPLYTA$1,004
- ZIMHI$999
- INVEGA SUSTENNA$571
- LYBALVI$468
- Austedo XR$467
- XEOMIN$430
- QELBREE$381
- INVEGA TRINZA$296
- INGREZZA$248
- Fanapt$244
- COBENFY$240
- INVEGA$127
- BELBUCA$124
- Auvelity$123
- AUSTEDO$120
- APTIOM$117
- Epidiolex$115
How this compares
$53,192 in reported general payments places this provider in the 95th percentile of 524 surgery providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 94 | $555,022 |
| Invega SustennaPaliperidone Palmitate | 143 | $408,036 |
| LybalviOlanzapine/Samidorphan Malate | 234 | $386,584 |
| AustedoDeutetrabenazine | 55 | $250,592 |
| RexultiBrexpiprazole | 164 | $250,064 |
| UzedyRisperidone | 62 | $210,390 |
| VraylarCariprazine Hcl | 143 | $200,840 |
| FanaptIloperidone | 66 | $183,560 |
| PerserisRisperidone | 48 | $131,680 |
| CaplytaLumateperone Tosylate | 77 | $130,750 |
| Paliperidone ErPaliperidone | 193 | $95,826 |
| Abilify MaintenaAripiprazole | 31 | $85,110 |
| OzempicSemaglutide | 80 | $81,171 |
| AuvelityDextromethorphan Hbr/Bupropion | 89 | $74,470 |
| Aripiprazole | 476 | $65,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $2,305 | $1,016,004211 claims |
| Alkermes, Inc.Lybalvi, Aristada | $362 | $441,411253 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $1,510 | $427,989176 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,633 | $335,174195 claims |
| AbbVieVraylar | $950 | $200,840143 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,667 | $183,56066 claims |
| Indivior Inc.Perseris | $536 | $131,68048 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,176 | $130,75077 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Nucynta | $71 | $100,646126 claims |
| Novo NordiskOzempic | $83 | $81,17180 claims |
| Axsome Therapeutics, Inc.Auvelity | $309 | $74,47089 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $134 | $63,371128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 surgery providers in Indiana.
Other surgery in Indianapolis
- Paul SzotekIndianapolis$2.4M
- Lewis JacobsonIndianapolis$761K
- Christian SchmidtIndianapolis$257K
- Jennifer ChoiIndianapolis$49K
- Marita BaumanIndianapolis$29K
- Don SelzerIndianapolis$24K
- Rosalie CarrIndianapolis$24K
- Steven MongIndianapolis$22K
- Jonathan MandelbaumIndianapolis$21K
- Jenalee CookseyIndianapolis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.